In this downloadable slideset, Mohammad Jahanzeb, MD, FACP, and Joyce O’Shaughnessy, MD, review key studies in early and advanced breast cancer presented at the 2015 San Antonio Breast Cancer Symposium
Mohammad Jahanzeb, MD, FACP, and Joyce O’Shaughnessy, MD, provide their analysis of key presentations from the 2015 San Antonio breast cancer meeting.
Longer follow-up demonstrated that the addition of palbociclib to fulvestrant maintained a significant PFS improvement in patients with MBC.
Abemaciclib combined with endocrine or HER2-targeted therapies was safe and active in patients with MBC.
In this phase II trial, the use of paclitaxel with neratinib plus trastuzumab increased pCR rate vs paclitaxel and either anti-HER2 agent alone in women with HER2+ locally advanced breast cancer.
Activity of investigational anti–PD-L1 monoclonal antibody in locally advanced or metastatic breast cancer is associated with PD-L1 expression.
Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy.
Adjuvant denosumab increased DFS in AI-treated postmenopausal women with early HR+ breast cancer.
Adding carboplatin to neoadjuvant chemotherapy significantly improved DFS in triple-negative but not HER2+ early breast cancer.
Greatest benefit seen in those with centrally confirmed HER2+ disease, completion of trastuzumab within 1 year of study entry, and hormone receptor–positive disease.
Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy.
This long-term follow-up analysis demonstrated a sustained advantage of adjuvant therapy with trastuzumab-containing regimens over the non-trastuzumab control in patients with HER2+ early breast cancer.
Use of trastuzumab emtansine improved survival in women with metastatic breast cancer and previous experience of anti-HER2 therapies compared with physician-selected therapy.
Preliminary data show efficacy and manageable toxicity in 25 patients with PD-L1+, ER+/HER2- advanced breast cancer.
The combination of the investigational PI3K inhibitor buparlisib with fulvestrant extended PFS in patients with HR+/HER2- advanced breast cancer who progressed on previous AI therapy.
This single-arm phase II study demonstrated enhanced cell cycle arrest with the addition of palbociclib to neoadjuvant anastrozole in patients with ER+/HER2- early breast cancer.
In patients with triple-negative breast cancer, 12 weeks of albumin-bound paclitaxel plus carboplatin significantly increased pCR rate vs albumin-bound paclitaxel plus gemcitabine.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.